OBJECTIVE: Thrombosis is an important cause of morbidity and mortality in SLE. We have explored the factors associated with time to the occurrence of thrombotic events in SLE patients to expand our cohort's previous observations. METHOD: SLE patients (ACR criteria), age >or=16 years, disease duration <or=5 years at enrollment (T0), African-American, Hispanic (Texan or Puerto Rican) or Caucasian ethnicity, from LUMINA, a longitudinal cohort, were studied. An event was defined as the presence of arterial or venous thrombosis. Time to the first thrombotic event was examined by univariable and multivariable (MV) Cox models adjusting for pertinent baseline clinical and socio-demographic variables. RESULTS: A total of 643 patients were studied; mean (s.d.) age was 36.4 (12.6) years and disease duration at T0 was 1.4 (1.3) years; 90% were female. After T0, 81 (12.6%) patients had developed a thrombotic event. In the MV model, age [hazard ratio (HR) = 1.06; 95% CI 1.03, 1.08; P < 0.0001], health insurance (HR = 0.53; 95% CI 0.30, 0.94; P = 0.029), smoking (HR = 1.85; 95% CI 1.01, 3.40; P = 0.048), damage (T0) (HR = 1.44; 95% CI 1.20, 1.71; P < 0.0001), aPL (HR = 2.12; 95% CI 1.19, 3.76; P = 0.011) and glucocorticoid (highest dose) (HR = 1.01; 95% CI 1.01, 1.02; P < 0.0001) were significant. CONCLUSIONS: Age, poverty, smoking, damage accrual, aPL and higher doses of glucocorticoids were independently associated with a shorter time to the first thrombotic event; health insurance had a protective effect. Acting upon modifiable risk factors at the personal (smoking, high-dose glucocorticoids) and societal (poverty, health insurance) levels may prevent these events and improve the long-term outcome of SLE patients.
OBJECTIVE:Thrombosis is an important cause of morbidity and mortality in SLE. We have explored the factors associated with time to the occurrence of thrombotic events in SLEpatients to expand our cohort's previous observations. METHOD:SLEpatients (ACR criteria), age >or=16 years, disease duration <or=5 years at enrollment (T0), African-American, Hispanic (Texan or Puerto Rican) or Caucasian ethnicity, from LUMINA, a longitudinal cohort, were studied. An event was defined as the presence of arterial or venous thrombosis. Time to the first thrombotic event was examined by univariable and multivariable (MV) Cox models adjusting for pertinent baseline clinical and socio-demographic variables. RESULTS: A total of 643 patients were studied; mean (s.d.) age was 36.4 (12.6) years and disease duration at T0 was 1.4 (1.3) years; 90% were female. After T0, 81 (12.6%) patients had developed a thrombotic event. In the MV model, age [hazard ratio (HR) = 1.06; 95% CI 1.03, 1.08; P < 0.0001], health insurance (HR = 0.53; 95% CI 0.30, 0.94; P = 0.029), smoking (HR = 1.85; 95% CI 1.01, 3.40; P = 0.048), damage (T0) (HR = 1.44; 95% CI 1.20, 1.71; P < 0.0001), aPL (HR = 2.12; 95% CI 1.19, 3.76; P = 0.011) and glucocorticoid (highest dose) (HR = 1.01; 95% CI 1.01, 1.02; P < 0.0001) were significant. CONCLUSIONS: Age, poverty, smoking, damage accrual, aPL and higher doses of glucocorticoids were independently associated with a shorter time to the first thrombotic event; health insurance had a protective effect. Acting upon modifiable risk factors at the personal (smoking, high-dose glucocorticoids) and societal (poverty, health insurance) levels may prevent these events and improve the long-term outcome of SLEpatients.
Authors: G S Alarcón; A W Friedman; K V Straaton; J M Moulds; J Lisse; H M Bastian; G McGwin; A A Bartolucci; J M Roseman; J D Reveille Journal: Lupus Date: 1999 Impact factor: 2.911
Authors: Ricard Cervera; Jean-Charles Piette; Josep Font; Munther A Khamashta; Yehuda Shoenfeld; María Teresa Camps; Soren Jacobsen; Gabriella Lakos; Angela Tincani; Irene Kontopoulou-Griva; Mauro Galeazzi; Pier Luigi Meroni; Ronald H W M Derksen; Philip G de Groot; Erika Gromnica-Ihle; Marta Baleva; Marta Mosca; Stefano Bombardieri; Frédéric Houssiau; Jean-Christophe Gris; Isabelle Quéré; Eric Hachulla; Carlos Vasconcelos; Beate Roch; Antonio Fernández-Nebro; Marie-Claire Boffa; Graham R V Hughes; Miguel Ingelmo Journal: Arthritis Rheum Date: 2002-04
Authors: K T Ho; C W Ahn; G S Alarcón; B A Baethge; F K Tan; J Roseman; H M Bastian; B J Fessler; G McGwin; L M Vilá; J Calvo-Alén; J D Reveille Journal: Rheumatology (Oxford) Date: 2005-07-19 Impact factor: 7.580
Authors: Mary J Roman; Beth-Ann Shanker; Adrienne Davis; Michael D Lockshin; Lisa Sammaritano; Ronit Simantov; Mary K Crow; Joseph E Schwartz; Stephen A Paget; Richard B Devereux; Jane E Salmon Journal: N Engl J Med Date: 2003-12-18 Impact factor: 91.245
Authors: Maria G Tektonidou; Flora Sotsiou; Lidia Nakopoulou; Panayiotis G Vlachoyiannopoulos; Haralampos M Moutsopoulos Journal: Arthritis Rheum Date: 2004-08
Authors: A Sisó; M Ramos-Casals; A Bové; P Brito-Zerón; N Soria; S Muñoz; A Testi; J Plaza; J Sentís; A Coca Journal: Lupus Date: 2008-04 Impact factor: 2.911
Authors: Maud Wieczorek; James Martin Gwinnutt; Maxime Ransay-Colle; Suzanne Mm Verstappen; Francis Guillemin; Andra Balanescu; Heike Bischoff-Ferrari; Annelies Boonen; Giulio Cavalli; Savia de Souza; Annette de Thurah; Thomas Ernst Dorner; Rikke Helene Moe; Polina Putrik; Javier Rodríguez-Carrio; Lucía Silva-Fernández; Tanja A Stamm; Karen Walker-Bone; Joep Welling; Mirjana Zlatkovic-Svenda Journal: RMD Open Date: 2022-03